HRP20191164T1 - C4-monometiltriterpenoidni derivati i postupci njihove upotrebe - Google Patents
C4-monometiltriterpenoidni derivati i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20191164T1 HRP20191164T1 HRP20191164TT HRP20191164T HRP20191164T1 HR P20191164 T1 HRP20191164 T1 HR P20191164T1 HR P20191164T T HRP20191164T T HR P20191164TT HR P20191164 T HRP20191164 T HR P20191164T HR P20191164 T1 HRP20191164 T1 HR P20191164T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkoxy
- alkylamino
- hydrogen
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452017P | 2011-03-11 | 2011-03-11 | |
| PCT/US2012/028569 WO2012125488A1 (en) | 2011-03-11 | 2012-03-09 | C4-monomethyl triterpenoid derivatives and methods of use thereof |
| EP12709768.1A EP2683731B1 (en) | 2011-03-11 | 2012-03-09 | C4-monomethyl triterpenoid derivatives and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191164T1 true HRP20191164T1 (hr) | 2019-10-04 |
Family
ID=45856041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191164TT HRP20191164T1 (hr) | 2011-03-11 | 2012-03-09 | C4-monometiltriterpenoidni derivati i postupci njihove upotrebe |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9290536B2 (https=) |
| EP (1) | EP2683731B1 (https=) |
| JP (1) | JP6129084B2 (https=) |
| KR (1) | KR101956399B1 (https=) |
| CN (1) | CN103619866B (https=) |
| AR (1) | AR085666A1 (https=) |
| AU (1) | AU2012229244B2 (https=) |
| BR (1) | BR112013023174B1 (https=) |
| CA (1) | CA2829618C (https=) |
| CL (1) | CL2013002612A1 (https=) |
| CO (1) | CO6801741A2 (https=) |
| CY (1) | CY1121744T1 (https=) |
| DK (1) | DK2683731T3 (https=) |
| EA (1) | EA026847B1 (https=) |
| ES (1) | ES2729405T3 (https=) |
| HR (1) | HRP20191164T1 (https=) |
| HU (1) | HUE044081T2 (https=) |
| IL (1) | IL228297B (https=) |
| LT (1) | LT2683731T (https=) |
| ME (1) | ME03469B (https=) |
| MX (1) | MX348862B (https=) |
| PL (1) | PL2683731T3 (https=) |
| PT (1) | PT2683731T (https=) |
| RS (1) | RS59200B1 (https=) |
| SG (1) | SG193404A1 (https=) |
| SI (1) | SI2683731T1 (https=) |
| SM (1) | SMT201900433T1 (https=) |
| TR (1) | TR201909788T4 (https=) |
| TW (1) | TWI535731B (https=) |
| UY (1) | UY33946A (https=) |
| WO (1) | WO2012125488A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| PL2252283T3 (pl) | 2008-01-11 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby |
| WO2009129546A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
| RS55631B1 (sr) | 2008-04-18 | 2017-06-30 | Reata Pharmaceuticals Inc | Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline |
| CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| ES2449396T3 (es) | 2008-07-22 | 2014-03-19 | Trustees Of Dartmouth College | Cianoenonas monocíclicas y métodos de uso de las mismas |
| PL2651902T3 (pl) | 2010-12-17 | 2018-04-30 | Reata Pharmaceuticals, Inc. | Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym |
| SI2683731T1 (sl) | 2011-03-11 | 2019-07-31 | Reata Pharmaceuticals, Inc. | C4-monometil triterpenoidni derivati in postopki njihove uporabe |
| JP6410710B2 (ja) * | 2012-04-27 | 2018-10-24 | リアタ ファーマシューティカルズ インコーポレイテッド | バルドキソロンメチルの２，２−ジフルオロプロピオンアミド誘導体、その多形体および使用方法 |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US20140088163A1 (en) * | 2012-09-10 | 2014-03-27 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| WO2014040060A1 (en) * | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
| MX2015003021A (es) * | 2012-09-10 | 2015-11-09 | Abbvie Inc | Derivados de acido glicirretinico y metodos de uso de los mismos. |
| WO2014148455A1 (ja) | 2013-03-19 | 2014-09-25 | 第一三共株式会社 | テルペノイド誘導体 |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| CA2814303A1 (en) | 2013-04-26 | 2014-10-26 | Cellphone-Mate, Inc. | Apparatus and methods for radio frequency signal boosters |
| CN104861027A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型齐墩果酸衍生物、其制备方法及其应用 |
| CN104861028A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型熊果酸衍生物、其制备方法及其应用 |
| US10208082B2 (en) | 2014-09-10 | 2019-02-19 | Daiichi Sankyo Company, Limited | Sustained-release pharmaceutical composition for treatment and prevention of eye disease |
| CN107428698B (zh) | 2015-02-12 | 2021-10-26 | 里亚塔医药公司 | 作为抗氧化炎症调节剂的咪唑基三环烯酮 |
| BR112018005861B1 (pt) | 2015-09-23 | 2022-11-22 | Reata Pharmaceuticals, Inc | Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos |
| CN105820207A (zh) * | 2016-03-24 | 2016-08-03 | 庄立 | 一种茴拉西坦的药物组合物及其抗氧化作用 |
| KR102486434B1 (ko) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| IL279348B2 (en) | 2018-06-15 | 2026-01-01 | Reata Pharmaceuticals Inc | Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma |
| WO2019246461A1 (en) | 2018-06-20 | 2019-12-26 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| BR112021005919A2 (pt) * | 2018-09-28 | 2021-07-27 | Sichuan Haisco Pharmaceutical Co., Ltd. | composto, composição farmacêutica e método para tratar uma doença em um mamífero |
| TWI861163B (zh) * | 2019-07-19 | 2024-11-11 | 美商瑞塔醫藥有限責任公司 | C17經極性取代之雜芳合成三萜類化合物及其使用方法 |
| US20240293351A1 (en) | 2020-12-11 | 2024-09-05 | Reata Pharmaceuticals Holdings, LLC | Methods of administering synthetic triterpenoids |
| EP4277916A1 (en) | 2021-01-18 | 2023-11-22 | Reata Pharmaceuticals, Inc. | Synthetic ursolic acid derivatives and methods of use thereof |
| JP2025508716A (ja) | 2022-02-16 | 2025-04-10 | フイルメニツヒ ソシエテ アノニム | オクタヒドロ－２（１ｈ）－ナフタレノン誘導体の製造方法 |
| GB202211190D0 (en) * | 2022-08-01 | 2022-09-14 | Royal College Surgeons Ireland | Fluorination process |
| CN117964678A (zh) * | 2024-01-29 | 2024-05-03 | 烟台大学 | C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| JP5059996B2 (ja) | 1999-05-14 | 2012-10-31 | ネレアス ファーマシューティカルズ インコーポレーテッド | 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法 |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| JP2001240573A (ja) | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
| AU2001294953A1 (en) | 2000-09-29 | 2002-04-08 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| US20040234977A1 (en) | 2001-05-14 | 2004-11-25 | Da-Wei Gong | Novel alanine transaminase enzyme and methods of use |
| DK1465615T3 (da) | 2002-01-15 | 2012-11-12 | Dartmouth College | Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf |
| JP2005519913A (ja) | 2002-01-18 | 2005-07-07 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 生物学的に活性な表面活性剤としてのトリテルペン第４アンモニウム塩 |
| AU2003303128A1 (en) | 2002-05-13 | 2004-08-13 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
| US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| WO2005046732A2 (en) | 2003-11-04 | 2005-05-26 | THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH | Methods and compositions for the inhibition of hiv-1 replication |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| EP1811840B1 (en) | 2004-09-07 | 2016-04-13 | May Sung Mak | Anti-tumor compounds with angeloyl groups |
| AU2006265113A1 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| WO2007112043A2 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
| WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| EP2032594B1 (en) | 2006-06-27 | 2015-09-23 | Wellington Laboratories Inc. | Glycyrrhetinic acid derivatives |
| CN101117348B (zh) | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| US7714012B2 (en) | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
| EP2680006A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| US20090048205A1 (en) | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
| US9012439B2 (en) | 2007-10-29 | 2015-04-21 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| PL2252283T3 (pl) | 2008-01-11 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby |
| WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| WO2009129546A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| RS55631B1 (sr) | 2008-04-18 | 2017-06-30 | Reata Pharmaceuticals Inc | Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline |
| CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
| ES2449396T3 (es) | 2008-07-22 | 2014-03-19 | Trustees Of Dartmouth College | Cianoenonas monocíclicas y métodos de uso de las mismas |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| SMT201900432T1 (it) | 2009-02-13 | 2019-09-09 | Reata Pharmaceuticals Inc | Composizioni di dosaggio orali, a rilascio ritardato contenenti cddo-me amorfo |
| CN101704874A (zh) * | 2009-11-26 | 2010-05-12 | 中国药科大学 | 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途 |
| MX357596B (es) | 2010-04-12 | 2018-07-16 | Reata Pharmaceuticals Inc | Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes. |
| WO2011140078A1 (en) | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| CN102070697A (zh) | 2010-12-09 | 2011-05-25 | 中国药科大学 | 一种齐墩果酸衍生物、其制备方法及用途 |
| KR101886467B1 (ko) | 2011-01-31 | 2018-08-07 | 비브 헬스케어 유케이 (넘버4) 리미티드 | Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드 |
| SI2683731T1 (sl) | 2011-03-11 | 2019-07-31 | Reata Pharmaceuticals, Inc. | C4-monometil triterpenoidni derivati in postopki njihove uporabe |
-
2012
- 2012-03-09 SI SI201231611T patent/SI2683731T1/sl unknown
- 2012-03-09 SM SM20190433T patent/SMT201900433T1/it unknown
- 2012-03-09 EA EA201391313A patent/EA026847B1/ru unknown
- 2012-03-09 JP JP2013557919A patent/JP6129084B2/ja active Active
- 2012-03-09 WO PCT/US2012/028569 patent/WO2012125488A1/en not_active Ceased
- 2012-03-09 HU HUE12709768A patent/HUE044081T2/hu unknown
- 2012-03-09 EP EP12709768.1A patent/EP2683731B1/en active Active
- 2012-03-09 RS RSP20190859 patent/RS59200B1/sr unknown
- 2012-03-09 AU AU2012229244A patent/AU2012229244B2/en active Active
- 2012-03-09 TR TR2019/09788T patent/TR201909788T4/tr unknown
- 2012-03-09 ES ES12709768T patent/ES2729405T3/es active Active
- 2012-03-09 PL PL12709768T patent/PL2683731T3/pl unknown
- 2012-03-09 KR KR1020137026782A patent/KR101956399B1/ko active Active
- 2012-03-09 SG SG2013068291A patent/SG193404A1/en unknown
- 2012-03-09 UY UY0001033946A patent/UY33946A/es not_active Application Discontinuation
- 2012-03-09 CA CA2829618A patent/CA2829618C/en active Active
- 2012-03-09 LT LTEP12709768.1T patent/LT2683731T/lt unknown
- 2012-03-09 HR HRP20191164TT patent/HRP20191164T1/hr unknown
- 2012-03-09 CN CN201280022645.4A patent/CN103619866B/zh active Active
- 2012-03-09 BR BR112013023174-2A patent/BR112013023174B1/pt active IP Right Grant
- 2012-03-09 ME MEP-2019-168A patent/ME03469B/me unknown
- 2012-03-09 DK DK12709768.1T patent/DK2683731T3/da active
- 2012-03-09 PT PT12709768T patent/PT2683731T/pt unknown
- 2012-03-09 MX MX2013010429A patent/MX348862B/es active IP Right Grant
- 2012-03-12 TW TW101108395A patent/TWI535731B/zh active
- 2012-03-12 US US13/417,519 patent/US9290536B2/en active Active
- 2012-03-12 AR ARP120100803A patent/AR085666A1/es unknown
-
2013
- 2013-09-08 IL IL228297A patent/IL228297B/en active IP Right Grant
- 2013-09-11 CL CL2013002612A patent/CL2013002612A1/es unknown
- 2013-10-09 CO CO13240105A patent/CO6801741A2/es not_active Application Discontinuation
-
2019
- 2019-07-01 CY CY20191100690T patent/CY1121744T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191164T1 (hr) | C4-monometiltriterpenoidni derivati i postupci njihove upotrebe | |
| HRP20191165T1 (hr) | C17-alkandiilni i alkendiilni derivati oleanolne kiseline i postupci njihove upotrebe | |
| JP7308263B2 (ja) | Ｃｔｐｓ１阻害剤としてのアミノピリミジン／ピラジン誘導体 | |
| ES2816382T3 (es) | Compuestos de alquinilbenceno heterocíclicos, y composiciones médicas y usos de los mismos | |
| JP2022009408A (ja) | カンナビノイド受容体モジュレーター | |
| JP2014508781A5 (https=) | ||
| SA519402216B1 (ar) | (jak)مثبطات صغيرة الجزيئات من فئة الكينازات مزدوجة الوجه | |
| JP2014501740A5 (https=) | ||
| UA118989C2 (uk) | Дигідропіролопіридинові інгібітори ror-гамма | |
| JP2017531688A5 (https=) | ||
| WO2018154520A1 (en) | Heterocyclic amides as kinase inhibitors | |
| NZ571691A (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | |
| JP2016518343A5 (https=) | ||
| US12240820B2 (en) | Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer | |
| WO2015075561A2 (en) | Crystalline forms of lesinurad and its sodium salt | |
| US11332494B2 (en) | Nanoemulsions and methods for cancer therapy | |
| Fernandes et al. | Biological assessment of novel bisphosphonate-containing 99mTc/Re-organometallic complexes | |
| UA112899C2 (uk) | Тверді форми n-((s)-2,3-дигідроксипропіл)-3-(2-фтор-4-йодфеніламіно)-ізонікотинаміду | |
| WO2023147015A1 (en) | Substituted heterocyclic csnk1 inhibitors | |
| UA129801C2 (uk) | Кристалічні форми інгібітора фосфоїнозитид-3-кінази (pi3k) | |
| JP2021534077A (ja) | Ｔｓｐｏ結合剤 | |
| EP4038054A1 (en) | Pyrimidinedione derivatives | |
| HUP0100957A2 (hu) | [(5-Szubsztituált-2-pirimidinil)-oxi]-karbonsav-származékok, előállításuk, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
| EP3177625A1 (en) | Amorphous form of 4-((4(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use | |
| CN103965162A (zh) | 磺酰胺类化合物及其制备方法和用途 |